menu
    • menu
    [{"orgOrder":0,"company":"Lindis Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Catumaxomab","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lindis Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intra-peritoneal infusion","sponsorNew":"Lindis Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lindis Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Lindis Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Catumaxomab","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Lindis Biotech","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Lindis Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lindis Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Lindis Biotech","sponsor":"Pharmanovia","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Large molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Catumaxomab","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Lindis Biotech","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Lindis Biotech \/ Pharmanovia","highestDevelopmentStatusID":"12","companyTruncated":"Lindis Biotech \/ Pharmanovia"}]

    Find Clinical Drug Pipeline Developments & Deals by Lindis Biotech

    Menu

    Lindis Biotech

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Lindis Biotech

                            Germany arrow
                            Antibody Engineering
                            Not Confirmed

                            Lindis Biotech

                            Germany arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Catumaxomab

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Pharmanovia

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Pharmanovia In-Licenses Catumaxomab for Malignant Ascites from Lindis Biotech

                            Details : The agreement gives Pharmanovia the exclusive rights to market, Korjuny (catumaxomab), a first-in-class, trifunctional bi-specific monoclonal antibody, indicated for malignant ascites in adults.

                            Brand Name : Korjuny

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            November 19, 2024

                            Lead Product(s) : Catumaxomab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Pharmanovia

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Lindis Biotech

                            Germany arrow
                            Antibody Engineering
                            Not Confirmed

                            Lindis Biotech

                            Germany arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Catumaxomab

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            LINDIS Biotech Receives Positive CHMP Opinion for KORJUNY(R) in EU

                            Details : Upon authorization by the European Commission, KORJUNY will be the only approved drug for malignant ascites in adults with epithelial cell adhesion molecule (EpCAM)-positive carcinomas

                            Brand Name : Korjuny

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            October 21, 2024

                            Lead Product(s) : Catumaxomab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Lindis Biotech

                            Germany arrow
                            Antibody Engineering
                            Not Confirmed

                            Lindis Biotech

                            Germany arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Catumaxomab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            LINDIS Biotech Reports Successful Initiation of Clinical Phase I Dose Escalation Study with the Trifunctional ...

                            Details : CATUMAXOMAB would be the first specific immunotherapy for non muscleinvasive bladder cancer, an indication with an extremely high unmet medical need.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            April 13, 2021

                            Lead Product(s) : Catumaxomab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth